Which has better valuation & earnings, JNJ or MRNA?

Johnson & Johnson has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Johnson & Johnson $94.19B 7.30 $26.80B $6.60 43.30 Moderna $1.94B 46.49 -$2.82B -$7.10 N/A

Is JNJ or MRNA more profitable?

Johnson & Johnson has a net margin of 16.20% compared to Moderna's net margin of -110.46%. Johnson & Johnson's return on equity of 31.64% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Johnson & Johnson 16.20% 31.64% 13.04% Moderna -110.46% -25.79% -15.85%

Does the media favor JNJ or MRNA?

In the previous week, Johnson & Johnson had 18 more articles in the media than Moderna. MarketBeat recorded 77 mentions for Johnson & Johnson and 59 mentions for Moderna. Johnson & Johnson's average media sentiment score of 0.92 beat Moderna's score of 0.58 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 45 Very Positive mention(s) 12 Positive mention(s) 12 Neutral mention(s) 3 Negative mention(s) 4 Very Negative mention(s) Positive Moderna 17 Very Positive mention(s) 15 Positive mention(s) 13 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Positive

Which has preferable valuation and earnings, NVAX or JNJ?

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.25 $440.30M -$0.46 N/A Johnson & Johnson $94.19B 7.30 $26.80B $6.60 43.30

Is NVAX or JNJ more profitable?

Johnson & Johnson has a net margin of 16.20% compared to Novavax's net margin of -18.64%. Johnson & Johnson's return on equity of 31.64% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -18.64% -14.82% -7.55% Johnson & Johnson 16.20% 31.64% 13.04%

Does the media refer more to NVAX or JNJ?

In the previous week, Johnson & Johnson had 63 more articles in the media than Novavax. MarketBeat recorded 77 mentions for Johnson & Johnson and 14 mentions for Novavax. Johnson & Johnson's average media sentiment score of 0.92 beat Novavax's score of 0.39 indicating that Johnson & Johnson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 1 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Johnson & Johnson 45 Very Positive mention(s) 12 Positive mention(s) 12 Neutral mention(s) 3 Negative mention(s) 4 Very Negative mention(s) Positive

Which has better valuation & earnings, JNJ or ABBV?

Johnson & Johnson has higher revenue and earnings than AbbVie. Johnson & Johnson is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Johnson & Johnson $94.19B 7.30 $26.80B $6.60 43.30 AbbVie $66.01B 7.90 $4.23B $5.81 50.81

Is JNJ or ABBV more profitable?

Johnson & Johnson has a net margin of 16.20% compared to AbbVie's net margin of 15.67%. Johnson & Johnson's return on equity of 31.64% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Johnson & Johnson 16.20% 31.64% 13.04% AbbVie 15.67% -450.55% 16.50%

Does the media favor JNJ or ABBV?

In the previous week, Johnson & Johnson had 32 more articles in the media than AbbVie. MarketBeat recorded 77 mentions for Johnson & Johnson and 45 mentions for AbbVie. AbbVie's average media sentiment score of 1.14 beat Johnson & Johnson's score of 0.92 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 45 Very Positive mention(s) 12 Positive mention(s) 12 Neutral mention(s) 3 Negative mention(s) 4 Very Negative mention(s) Positive AbbVie 35 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, JNJ or AZN?

Johnson & Johnson has higher revenue and earnings than AstraZeneca. AstraZeneca is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Johnson & Johnson $94.19B 7.30 $26.80B $6.60 43.30 AstraZeneca $58.74B 4.88 $10.23B $7.07 26.12

Does the media refer more to JNJ or AZN?

In the previous week, Johnson & Johnson had 61 more articles in the media than AstraZeneca. MarketBeat recorded 77 mentions for Johnson & Johnson and 16 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 1.21 beat Johnson & Johnson's score of 0.92 indicating that AstraZeneca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 45 Very Positive mention(s) 12 Positive mention(s) 12 Neutral mention(s) 3 Negative mention(s) 4 Very Negative mention(s) Positive AstraZeneca 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to JNJ or LLY?

In the previous week, Eli Lilly and Company had 60 more articles in the media than Johnson & Johnson. MarketBeat recorded 137 mentions for Eli Lilly and Company and 77 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 0.92 beat Eli Lilly and Company's score of 0.66 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 45 Very Positive mention(s) 12 Positive mention(s) 12 Neutral mention(s) 3 Negative mention(s) 4 Very Negative mention(s) Positive Eli Lilly and Company 59 Very Positive mention(s) 35 Positive mention(s) 23 Neutral mention(s) 13 Negative mention(s) 5 Very Negative mention(s) Positive

Johnson & Johnson (JNJ) Competitors

$285.78 +2.26 (+0.80%)

Closing price 11/13/2026 03:59 PM Eastern

Extended Trading

$286.81 +1.03 (+0.36%)

As of 11/13/2026 07:57 PM Eastern

Compare

JNJ vs. MRNA, NVAX, ABBV, AZN, and LLY

Should you buy Johnson & Johnson stock or one of its competitors? Johnson & Johnson's main competitors and comparable companies include Moderna (MRNA), Novavax (NVAX), AbbVie (ABBV), AstraZeneca (AZN), and Eli Lilly and Company (LLY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Johnson & Johnson compare to Moderna?

Johnson & Johnson (NYSE:JNJ) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Johnson & Johnson has a net margin of 16.20% compared to Moderna's net margin of -110.46%. Johnson & Johnson's return on equity of 31.64% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	16.20%	31.64%	13.04%
Moderna	-110.46%	-25.79%	-15.85%

Johnson & Johnson has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market. Comparatively, Moderna has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

Johnson & Johnson presently has a consensus target price of $275.92, indicating a potential downside of 3.45%. Moderna has a consensus target price of $113.75, indicating a potential downside of 49.08%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, research analysts plainly believe Johnson & Johnson is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	8 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.73
Moderna	4 Sell rating(s)	15 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.08

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Johnson & Johnson has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	7.30	$26.80B	$6.60	43.30
Moderna	$1.94B	46.49	-$2.82B	-$7.10	N/A

In the previous week, Johnson & Johnson had 18 more articles in the media than Moderna. MarketBeat recorded 77 mentions for Johnson & Johnson and 59 mentions for Moderna. Johnson & Johnson's average media sentiment score of 0.92 beat Moderna's score of 0.58 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	45 Very Positive mention(s)	12 Positive mention(s)	12 Neutral mention(s)	3 Negative mention(s)	4 Very Negative mention(s)	Positive
Moderna	17 Very Positive mention(s)	15 Positive mention(s)	13 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Positive

Summary

Johnson & Johnson beats Moderna on 12 of the 16 factors compared between the two stocks.

How does Johnson & Johnson compare to Novavax?

Novavax (NASDAQ:NVAX) and Johnson & Johnson (NYSE:JNJ) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

53.0% of Novavax shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Novavax currently has a consensus target price of $12.33, indicating a potential upside of 44.76%. Johnson & Johnson has a consensus target price of $275.92, indicating a potential downside of 3.45%. Given Novavax's higher possible upside, research analysts plainly believe Novavax is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20
Johnson & Johnson	0 Sell rating(s)	8 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.73

Novavax has a beta of 2.65, meaning that its stock price is 165% more volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market.

Johnson & Johnson has a net margin of 16.20% compared to Novavax's net margin of -18.64%. Johnson & Johnson's return on equity of 31.64% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-18.64%	-14.82%	-7.55%
Johnson & Johnson	16.20%	31.64%	13.04%

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.25	$440.30M	-$0.46	N/A
Johnson & Johnson	$94.19B	7.30	$26.80B	$6.60	43.30

In the previous week, Johnson & Johnson had 63 more articles in the media than Novavax. MarketBeat recorded 77 mentions for Johnson & Johnson and 14 mentions for Novavax. Johnson & Johnson's average media sentiment score of 0.92 beat Novavax's score of 0.39 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	1 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Johnson & Johnson	45 Very Positive mention(s)	12 Positive mention(s)	12 Neutral mention(s)	3 Negative mention(s)	4 Very Negative mention(s)	Positive

Summary

Johnson & Johnson beats Novavax on 13 of the 16 factors compared between the two stocks.

How does Johnson & Johnson compare to AbbVie?

Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 1.9%. AbbVie pays an annual dividend of $7.28 per share and has a dividend yield of 2.5%. Johnson & Johnson pays out 81.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie pays out 125.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson has increased its dividend for 64 consecutive years and AbbVie has increased its dividend for 53 consecutive years.

Johnson & Johnson has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market.

Johnson & Johnson has a net margin of 16.20% compared to AbbVie's net margin of 15.67%. Johnson & Johnson's return on equity of 31.64% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	16.20%	31.64%	13.04%
AbbVie	15.67%	-450.55%	16.50%

Johnson & Johnson has higher revenue and earnings than AbbVie. Johnson & Johnson is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	7.30	$26.80B	$6.60	43.30
AbbVie	$66.01B	7.90	$4.23B	$5.81	50.81

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Johnson & Johnson had 32 more articles in the media than AbbVie. MarketBeat recorded 77 mentions for Johnson & Johnson and 45 mentions for AbbVie. AbbVie's average media sentiment score of 1.14 beat Johnson & Johnson's score of 0.92 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	45 Very Positive mention(s)	12 Positive mention(s)	12 Neutral mention(s)	3 Negative mention(s)	4 Very Negative mention(s)	Positive
AbbVie	35 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Johnson & Johnson presently has a consensus price target of $275.92, indicating a potential downside of 3.45%. AbbVie has a consensus price target of $297.46, indicating a potential upside of 0.77%. Given AbbVie's stronger consensus rating and higher probable upside, analysts plainly believe AbbVie is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	8 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.73
AbbVie	0 Sell rating(s)	6 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Johnson & Johnson beats AbbVie on 10 of the 19 factors compared between the two stocks.

How does Johnson & Johnson compare to AstraZeneca?

Johnson & Johnson (NYSE:JNJ) and AstraZeneca (NYSE:AZN) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 1.9%. AstraZeneca pays an annual dividend of $2.17 per share and has a dividend yield of 1.2%. Johnson & Johnson pays out 81.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AstraZeneca pays out 30.7% of its earnings in the form of a dividend. Johnson & Johnson has increased its dividend for 64 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Johnson & Johnson currently has a consensus price target of $275.92, suggesting a potential downside of 3.45%. AstraZeneca has a consensus price target of $206.67, suggesting a potential upside of 11.91%. Given AstraZeneca's stronger consensus rating and higher possible upside, analysts clearly believe AstraZeneca is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	8 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.73
AstraZeneca	0 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.84

AstraZeneca has a net margin of 17.68% compared to Johnson & Johnson's net margin of 16.20%. AstraZeneca's return on equity of 31.85% beat Johnson & Johnson's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	16.20%	31.64%	13.04%
AstraZeneca	17.68%	31.85%	13.62%

Johnson & Johnson has higher revenue and earnings than AstraZeneca. AstraZeneca is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	7.30	$26.80B	$6.60	43.30
AstraZeneca	$58.74B	4.88	$10.23B	$7.07	26.12

In the previous week, Johnson & Johnson had 61 more articles in the media than AstraZeneca. MarketBeat recorded 77 mentions for Johnson & Johnson and 16 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 1.21 beat Johnson & Johnson's score of 0.92 indicating that AstraZeneca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	45 Very Positive mention(s)	12 Positive mention(s)	12 Neutral mention(s)	3 Negative mention(s)	4 Very Negative mention(s)	Positive
AstraZeneca	11 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Johnson & Johnson has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 20.4% of AstraZeneca shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Johnson & Johnson beats AstraZeneca on 11 of the 20 factors compared between the two stocks.

How does Johnson & Johnson compare to Eli Lilly and Company?

Johnson & Johnson (NYSE:JNJ) and Eli Lilly and Company (NYSE:LLY) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Johnson & Johnson has higher revenue and earnings than Eli Lilly and Company. Johnson & Johnson is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	7.30	$26.80B	$6.60	43.30
Eli Lilly and Company	$65.18B	20.84	$20.64B	$30.81	46.87

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Johnson & Johnson presently has a consensus target price of $275.92, suggesting a potential downside of 3.45%. Eli Lilly and Company has a consensus target price of $1,416.64, suggesting a potential downside of 1.90%. Given Eli Lilly and Company's stronger consensus rating and higher probable upside, analysts plainly believe Eli Lilly and Company is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	8 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.73
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.83

Eli Lilly and Company has a net margin of 31.90% compared to Johnson & Johnson's net margin of 16.20%. Eli Lilly and Company's return on equity of 86.76% beat Johnson & Johnson's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	16.20%	31.64%	13.04%
Eli Lilly and Company	31.90%	86.76%	22.03%

Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 1.9%. Eli Lilly and Company pays an annual dividend of $6.92 per share and has a dividend yield of 0.5%. Johnson & Johnson pays out 81.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Eli Lilly and Company pays out 22.5% of its earnings in the form of a dividend. Johnson & Johnson has increased its dividend for 64 consecutive years and Eli Lilly and Company has increased its dividend for 11 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Eli Lilly and Company had 60 more articles in the media than Johnson & Johnson. MarketBeat recorded 137 mentions for Eli Lilly and Company and 77 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 0.92 beat Eli Lilly and Company's score of 0.66 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	45 Very Positive mention(s)	12 Positive mention(s)	12 Neutral mention(s)	3 Negative mention(s)	4 Very Negative mention(s)	Positive
Eli Lilly and Company	59 Very Positive mention(s)	35 Positive mention(s)	23 Neutral mention(s)	13 Negative mention(s)	5 Very Negative mention(s)	Positive

Johnson & Johnson has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

Summary

Eli Lilly and Company beats Johnson & Johnson on 13 of the 19 factors compared between the two stocks.

Get Johnson & Johnson News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JNJ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JNJ vs. The Competition

Export

Metric	Johnson & Johnson	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$682.52B	$13.77B	$7.84B	$23.48B
Dividend Yield	1.89%	2.56%	2.46%	3.78%
P/E Ratio	43.30	29.40	34.71	27.05
Price / Sales	7.30	7.34	8.66	3.38
Price / Cash	20.08	15.74	21.93	15.51
Price / Book	8.44	4.93	4.35	3.72
Net Income	$26.80B	$2.88B	$3.51B	$1.08B
7 Day Performance	3.49%	-0.21%	-1.49%	0.58%
1 Month Performance	12.74%	-3.25%	-2.55%	1.11%
1 Year Performance	45.80%	-6.14%	0.92%	7.21%

Johnson & Johnson Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JNJ Johnson & Johnson	3.2902 of 5 stars	$285.78 +0.8%	$275.92 -3.5%	+46.4%	$682.52B	$94.19B	43.30	138,200	Trending News Insider Trade
MRNA Moderna	1.5443 of 5 stars	$255.63 -5.0%	$113.75 -55.5%	+794.9%	$102.08B	$1.94B	N/A	4,700	Trending News Earnings Report Analyst Revision Gap Down
NVAX Novavax	2.1375 of 5 stars	$10.24 -6.0%	$12.33 +20.5%	+20.7%	$1.69B	$1.12B	N/A	749
ABBV AbbVie	3.793 of 5 stars	$293.58 +0.1%	$297.46 +1.3%	+27.1%	$519.37B	$61.16B	50.57	57,000	Trending News Insider Trade
AZN AstraZeneca	4.5832 of 5 stars	$186.09 -1.7%	$206.67 +11.1%	+4.2%	$289.20B	$58.74B	26.38	96,100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:JNJ) was last updated on 11/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Johnson & Johnson (JNJ) Competitors

JNJ vs. MRNA, NVAX, ABBV, AZN, and LLY

How does Johnson & Johnson compare to Moderna?

Summary

How does Johnson & Johnson compare to Novavax?

Summary

How does Johnson & Johnson compare to AbbVie?

Summary

How does Johnson & Johnson compare to AstraZeneca?

Summary

How does Johnson & Johnson compare to Eli Lilly and Company?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JNJ vs. The Competition

Johnson & Johnson Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Johnson & Johnson (JNJ) Competitors

JNJ vs. MRNA, NVAX, ABBV, AZN, and LLY

How does Johnson & Johnson compare to Moderna?

Is JNJ or MRNA more profitable?

Which has more risk and volatility, JNJ or MRNA?

Do analysts prefer JNJ or MRNA?

Do institutionals and insiders believe in JNJ or MRNA?

Which has better valuation & earnings, JNJ or MRNA?

Does the media favor JNJ or MRNA?

Summary

How does Johnson & Johnson compare to Novavax?

Do institutionals and insiders have more ownership in NVAX or JNJ?

Do analysts rate NVAX or JNJ?

Which has more volatility & risk, NVAX or JNJ?

Is NVAX or JNJ more profitable?

Which has preferable valuation and earnings, NVAX or JNJ?

Does the media refer more to NVAX or JNJ?

Summary

How does Johnson & Johnson compare to AbbVie?

Is JNJ or ABBV a better dividend stock?

Which has more volatility & risk, JNJ or ABBV?

Is JNJ or ABBV more profitable?

Which has better valuation & earnings, JNJ or ABBV?

Do insiders and institutionals have more ownership in JNJ or ABBV?

Does the media favor JNJ or ABBV?

Do analysts recommend JNJ or ABBV?

Summary

How does Johnson & Johnson compare to AstraZeneca?

Is JNJ or AZN a better dividend stock?

Do analysts prefer JNJ or AZN?

Is JNJ or AZN more profitable?

Which has stronger valuation & earnings, JNJ or AZN?

Does the media refer more to JNJ or AZN?

Which has more volatility and risk, JNJ or AZN?

Do insiders and institutionals hold more shares of JNJ or AZN?

Summary

How does Johnson & Johnson compare to Eli Lilly and Company?

Which has stronger valuation and earnings, JNJ or LLY?

Do insiders & institutionals have more ownership in JNJ or LLY?

Do analysts recommend JNJ or LLY?

Is JNJ or LLY more profitable?

Is JNJ or LLY a better dividend stock?

Does the media refer more to JNJ or LLY?

Which has more volatility and risk, JNJ or LLY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JNJ vs. The Competition

Johnson & Johnson Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools